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ABSTRACT
Objective: To explore an association with survival of modifying the current standard of care for
patients with newly diagnosed glioblastoma of surgery followed by radiotherapy plus concurrent
and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT/ TMZ) by extending TMZ
beyond 6 cycles.
Methods: The German Glioma Network cohort was screened for patients with newly diagnosed
glioblastoma who received TMZ/RT / TMZ and completed $6 cycles of maintenance chemo-
therapy without progression. Associations of clinical patient characteristics, molecular markers,
and residual tumor determined by magnetic resonance imaging after 6 cycles of TMZ with
progression-free survival (PFS) and overall survival (OS) were analyzed with the log-rank test.
Multivariate analyses using the Cox proportional hazards model were performed to assess asso-
ciations of prolonged TMZ use with outcome.
Results: Sixty-one of 142 identified patients received at least 7 maintenance TMZ cycles (median
11, range 7–20). Patients with extended maintenance TMZ treatment had better PFS (20.5
months, 95% confidence interval [CI] 17.7–23.3, vs 17.2 months, 95% CI 10.2–24.2, p 5
0.035) but not OS (32.6 months, 95% CI 28.9–36.4, vs 33.2 months, 95% CI 25.3–41.0,
p 5 0.126). However, there was no significant association of prolonged TMZ chemotherapy with
PFS (hazard ratio [HR]5 0.8, 95%CI 0.4–1.6, p5 0.559) or OS (HR5 1.6, 95%CI 0.8–3.3, p5
0.218) adjusted for age, extent of resection, Karnofsky performance score, presence of residual
tumor, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status, or
isocitrate dehydrogenase (IDH) mutation status.
Conclusion: These data may not support the practice of prolonging maintenance TMZ chemother-
apy beyond 6 cycles.
Classification of evidence: This study provides Class III evidence that in patients with newly diag-
nosed glioblastoma, prolonged TMZ chemotherapy does not significantly increase PFS or OS.
Neurology® 2017;88:1422–1430
GLOSSARY
CI 5 confidence interval; GGN 5 German Glioma Network; HR 5 hazard ratio; IDH 5 isocitrate dehydrogenase; KPS 5
Karnofsky performance score; MGMT 5 O6-methylguanine DNA methyltransferase; OS 5 overall survival; PFS 5 progres-
sion-free survival; RT 5 radiotherapy; STROBE 5 Strengthening the Reporting of Observational Studies in Epidemiology;
TMZ 5 temozolomide.
Glioblastoma is an intrinsic brain tumor with an annual incidence of 3 per 100,000 individuals
worldwide. Patients eligible for multimodality treatment commonly have biopsy or resection as
feasible and then postoperative radiotherapy (RT) plus concomitant and 6 cycles of maintenance
temozolomide chemotherapy (TMZ/RT / TMZ).1–3 At a population level, median overall
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survival (OS) has markedly improved from the
pre-TMZ to the TMZ era.4 A few smaller,
single-institution, retrospective studies claimed
prolonged survival of patients with glioblastoma
who received extended TMZ treatment beyond
6 cycles.5–8 The major limitation of all these
studies, beyond the retrospective nature, is the
comparison of patients who were treated with at
least 7 cycles of TMZ to patients who received
#6 cycles and therefore to patients who in most
cases stopped TMZ because of tumor progres-
sion. Long-term administration of TMZ was
associated with an acceptable safety profile in
patients diagnosed with World Health Organi-
zation grade III and IV gliomas who received
long-term TMZ treatment for at least 12
cycles.9 Preliminary data from a large pooled
analysis of 4 clinical trials (EORTC26981-
NCIC CE.3, Radiation Therapy Oncology
Group 0525, EORTC26071-CENTRIC,
CORE)3,10–12 indicate that extended treatment
with TMZ beyond 6 cycles is not associated
with improved OS but with improved
progression-free survival (PFS) (hazard ratio
[HR] 0.8, 95% confidence interval [CI]
0.6–1) compared to patients who received
exactly 6 cycles of TMZ, especially in patients
with O6-methylguanine DNA methyltransferase
(MGMT) promoter–methylated tumors (HR 5
0.6, 95% CI 0.5–0.9).13 Here, we performed
a similar analysis in patients enrolled in the
German Glioma Network (GGN), a prospective
cohort study, with a focus on the role ofMGMT
promoter methylation status and extent of
residual disease after 6 cycles of adjuvant TMZ.
METHODS Standard protocol approvals, registrations,
and patient consents. The GGN is a prospective cohort study
involving 8 clinical centers at university hospitals in Germany that
included 2,002 patients diagnosed with glioblastoma fromOctober
2004 to October 2010 (http://www.gliomnetzwerk.de). Informed
consent was signed by all patients. This study was approved by the
review committees of the participating centers.
The primary research question of the present study was to
explore a survival benefit from extending maintenance TMZ che-
motherapy beyond 6 cycles in patients with newly diagnosed glio-
blastoma who received TMZ/RT/ TMZ. The study is rated
Class III because of the absence of randomization and because of
differences in baseline characteristics of treatment groups.
This manuscript was prepared in accordance with Strength-
ening the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines.14
Patients and tumors. The present study evaluated clinical fea-
tures and survival data in patients with newly diagnosed
glioblastoma who received TMZ/RT/ TMZ (n 5 142) with
at least 6 cycles of maintenance chemotherapy without progression.
The number of cycles was left to the discretion of the sites, and no
recommendation was made as part of the GGN cohort study. Diag-
nosis of glioblastoma was confirmed according to the World Health
Organization classification of tumors of the CNS15 by central pathol-
ogy review, and clinical data were collected as described.16 The meth-
ylation status of the MGMT gene promoter region was assessed by
methylation-specific PCR.17 Analyses for isocitrate dehydrogenase
(IDH) 1 or IDH2 gene mutations were performed by DNA
pyrosequencing,18 or by immunohistochemistry for IDH1-R132H
protein. Formaldehyde-fixed paraffin-embedded sections 4 mm
thick were cut from the tumors. After deparaffinization and antigen
retrieval, mutated IDH1-R132H protein was detected by the murine
monoclonal mutation–specific antibody clone H09 (Dianova,
Hamburg, Germany) with the ultraViewUniversal DAB detection kit
and a Benchmark XT immunostaining system (Ventana-Roche,
Mannheim, Germany). Extent of resection was determined by early
(,72 hours) postoperative imaging byMRI or by CTwhenMRI was
not feasible or not available. Treatment decisions were made by the
treating physicians, patients, and their families, commonly without
awareness of the MGMT promoter methylation status; 35 patients
were included in previous publications.16,19–25
MRI scans or at least written reports were collected at the
time point when 6 cycles of TMZ chemotherapy were completed
to assess tumor status. MRI scans of 36 patients were available for
central radiology assessment (P.K., M.B.) according to Response
Assessment in Neuro-Oncology criteria. Written neuroradiology
reports were provided from 51 additional patients. Data on resid-
ual tumor were available from a total of 87 patients. Residual
tumor was defined by contrast-enhancing lesions.
To avoid bias that occurs when groups to be compared are
determined during study follow-up, all patients who had died
or had progressive disease before completion of 6 cycles TMZ
were excluded.
Statistics. PFS and OS curves were generated with the Kaplan-
Meier method and compared by the log-rank test. PFS was
calculated from the day of surgery until progression, death, or
end of follow-up. OS was measured from the day of surgery to
the date of death or end of follow-up. At the time of last
follow-up, all patients who had not died were censored. The x2
and Fisher exact tests were performed for analysis of nominal
variables, and the Student t test was performed for quantitative
variables. Cox proportional hazards regression models were used
for univariate and multivariate analyses to test the association of
clinical factors, residual tumor burden after 6 cycles of maintenance
TMZ, and IDH mutation status and MGMT promoter
methylation status with outcome. For the multivariate model,
patients who had complete information on all tested covariables
were included (age, extent of resection, Karnofsky performance
score [KPS] at the time of diagnosis, MGMT promoter
methylation status, IDH mutation status, residual tumor after 6
cycles of maintenance TMZ). A landmark analysis with a 7-month
landmark was performed to estimate landmark PFS and landmark
OS after the end of the 6 cycles of maintenance TMZ. All statistical
tests were 2 tailed. A value of p 5 0.05 was defined as statistically
significant. All statistical analyses were performed with IBM
(Armonk, NY) SPSS Statistics version 24.0.
RESULTS Patient characteristics. The principal
patient characteristics are summarized in table 1 and
table e-1 at Neurology.org. A total of 142 patients with
newly diagnosed glioblastoma were identified in the
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GGN database (figure e-1). Patients were divided into
2 groups defined by the number of TMZ cycles: 6
cycles (group A, n 5 81) and $7 cycles (group B,
n 5 61). The median number of TMZ cycles in
group B was 11 (range 7–20). Table 1 shows that
both groups were balanced for age (p 5 0.359), sex
(p5 0.752), extent of resection (p5 0.420), and KPS
(p 5 0.105). The MGMT promoter methylation
status of the tumor was available in 132 patients: 77
patients had MGMT promoter–methylated tumors
(58.3%); 59.7% (group A) vs 56.7% (group B) of
patients demonstrated a methylatedMGMT promoter
(p 5 0.723). The high proportion of MGMT
promoter–methylated tumors reflects the selection bias
induced by studying patients who received at least 6
cycles of TMZ. The IDHmutation status was available
in 128 patients: 7 patients in group A (9.7%) had
IDH-mutant tumors vs 10 patients in group B (17.
9%) (p 5 0.179). Data on residual tumor (contrast-
enhancing tumor; written neuroradiologic reports or
central neuroradiologic assessment) at completion of 6
cycles were available in 45 patients in group A (55.6%)
and in 42 patients in group B (68.9%). Residual tumor
after 6 cycles of maintenance TMZwas described in 16
patients in group A (35.6%) and in 22 patients in
group B (52.4%) (p 5 0.114). In the subgroup of
patients with MRI scans available, central radiologic
assessment demonstrated residual tumor in 7 of 15
patients in group A (46.7%) and in 12 of 21 patients in
group B (57.1%) (p 5 0.535).
Outcome data. The median time of follow-up was
77.0 months in the whole patient cohort: 68.4
months in group A and 77.0 months in group B.
Median PFS was 20.0 months (95% CI 17.0–22.8)
and median OS was 33.2 months (95% CI 29.2–
37.1) in the whole patient cohort. Median PFS was
17.2 months (95% CI 10.2–24.2) in group A
compared to 20.5 months (95% CI 17.7–23.3) in
group B (p 5 0.035). Median OS was 33.2 months
(95% CI 25.3–41.0) in group A compared to 32.6
months (95% CI 28.9–36.4) in group B (p5 0.126)
(table 2 and figure 1A). MGMT promoter
methylation was associated with increased PFS (p ,
0.001) and OS (p 5 0.004) (figure e-2A). In the
subgroup of patients with MGMT promoter–
methylated tumors, neither PFS (25.9 [group A] vs
22.5 months [group B], p 5 0.377) nor OS (41.3 vs
36.1 months, p 5 0.649) differed between groups
(table 2 and figure 1B). In patients with MGMT
promoter–unmethylated tumors, increased PFS was
observed in patients with extended TMZ treatment
(10.9 [group A] vs 14.9 months [group B], p 5
0.012), whereas no difference was seen for OS (24.7
vs 26.9 months, p 5 0.132) (table 2 and figure 1B).
Absence vs presence of residual tumor after 6 cycles of
maintenance TMZ was strongly prognostic (PFS p,
0.001; OS p , 0.001) (figure e-2B). However,
extended TMZ treatment beyond 6 cycles was not
Table 1 Summary of patient characteristics
Group A, 6
cycles of TMZ
Group B, ‡7
cycles of TMZ p Value
No. 81 61
TMZ cycles, n
Median 6 11 ,0.001
Range 6–6 7–20
Age at diagnosis, y
Median 58 55 0.359
Range 23–77 27–74
Age classes, n (%)
£65 y 69 (85.2) 51 (83.6) 0.797
>65 y 12 (14.8) 10 (16.4)
Sex, n (%)
Male 47 (58.0) 37 (60.7) 0.752
Female 34 (42.0) 24 (39.3)
Extent of resection, n (%)
Gross total 42 (59.2) 29 (48.3) 0.420
Incomplete 21 (29.6) 24 (40.0)
Biopsy 8 (11.3) 7 (11.7)
No data 10 1
KPS at enrollment, n (%)
£80 37 (53.6) 18 (38.3) 0.105
90–100 32 (46.4) 29 (61.7)
No data 12 14
MGMT promoter methylation
status, n (%)
Methylated 43 (59.7) 34 (56.7) 0.723
Unmethylated 29 (40.3) 26 (43.3)
No data 9 1
IDH1/2 status, n (%)
Mutant 7 (9.7) 10 (17.9) 0.179
Wild-type 65 (90.3) 46 (82.1)
No data 9 5
Residual tumor,a n (%)
Yes 16 (35.6) 22 (52.4) 0.114
No 29 (64.4) 20 (47.6)
No data 36 19
Residual tumor,a,b n (%)
Yes 7 (46.7) 12 (57.1) 0.535
No 8 (53.3) 9 (42.9)
No data 66 40
Abbreviations: IDH 5 isocitrate dehydrogenase; MGMT 5 O6-methylguanine DNA methyl-
transferase; KPS 5 Karnofsky performance score; TMZ 5 temozolomide.
a After 6 cycles of maintenance TMZ chemotherapy.
bOnly patients available for central radiology review.
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associated with outcome in patients with confirma-
tion of residual tumor after 6 cycles of TMZ treat-
ment (PFS 12.3 months [group A] vs 14.6 months
[group B], p 5 0.461; OS 21.3 vs 21.8 months, p 5
0.597) (table 2 and figure 1C). Similar results were
observed when only patients with central reference
radiology were included (PFS 13.4 [group A] vs 13.4
months [group B], p 5 0.956; OS 16.2 vs 21.8
months, p 5 0.904) (table 2 and figure 1D). Similar
outcome by group was also observed in patients
without residual tumor (PFS 25.0 [group A] vs 23.0
months [group B], p 5 0.148; OS 44.7 vs 41.4
months, p 5 0.515; patients with central reference
radiology: PFS 22.0 vs 22.5 months, p 5 0.512; OS
47.2 vs 41.4 months, p 5 0.928) (table 2 and figure
1, C and D). The apparent plateau in group B in
patients without residual tumor results from a larger
number of long-term surviving patients with IDH-
mutant glioblastomas. For patients without tumor
burden after 6 cycles of TMZ and with OS .48
months, IDH mutations were observed in 5 of 9
patients in group B and in 2 of 11 patients in
group A.
In addition, a 7-month landmark analysis was per-
formed to estimate PFS and OS after the end of the 6
cycles of maintenance TMZ (figure e-3). Median land-
mark PFS was 10.2 months (95% CI 3.2–17.2) for
group A and 13.5 months (95% CI 10.7–16.3) for
group B (p 5 0.035), and landmark OS was 26.2
months (95% CI 18.3–34.0) for group A and 25.6
months (95%CI 21.9–29.4) for group B (p5 0.126).
Association of age, sex, extent of resection, KPS, MGMT
promoter methylation status, IDH mutation status,
residual tumor, and TMZ cycles with outcome. Patients
were divided into 2 groups defined by age, sex, extent
of resection, KPS,MGMT promoter methylation sta-
tus, IDH mutation status, residual tumor, and TMZ
cycles. Univariate analysis using the Cox proportional
hazard model was performed to assess their association
with PFS or OS. Extent of resection, MGMT pro-
moter methylation status, IDH mutation status, and
residual tumor burden after 6 cycles of maintenance
TMZ, but not age, sex, KPS, or extended TMZ treat-
ment, were risk factors for progression. In addition,
age, extent of resection,MGMT promoter methylation
status, IDHmutation status, and residual tumor after 6
Table 2 Kaplan-Meier survival data: Subgroup analysis
No. (events) Median PFS (95% CI), mo P (log-rank) No. (events) Median OS (95% CI), mo P (log-rank)
All patients
6 cycles of TMZ (A) 81 (77) 17.18 (10.20–24.16) 0.035 81 (69) 33.15 (25.26–41.03) 0.126
‡7 cycles of TMZ (B) 61 (52) 20.49 (17.66–23.33) 61 (44) 32.62 (28.86–36.39)
Methylated MGMT promoter
6 cycles of TMZ 43 (39) 25.87 (19.72–32.02) 0.377 43 (34) 41.28 (31.23–51.33) 0.649
‡7 cycles of TMZ 34 (27) 22.53 (17.84–27.21) 34 (24) 36.10 (24.58–47.62)
Unmethylated MGMT promoter
6 cycles of TMZ 29 (29) 10.89 (10.48–11.29) 0.012 29 (27) 24.69 (18.64–30.74) 0.132
‡7 cycles of TMZ 26 (25) 14.92 (9.88–19.97) 26 (20) 26.85 (15.93–37.78)
No residual tumora
6 cycles of TMZ 29 (27) 24.98 (18.41–31.56) 0.148 29 (22) 44.69 (34.69–54.69) 0.515
‡7 cycles of TMZ 20 (14) 22.95 (14.55–31.36) 20 (11) 41.38 (10.40–72.35)
No residual tumora,b
6 cycles of TMZ 8 (8) 22.00 (9.64–34.36) 0.512 8 (7) 47.21 (27.67–66.75) 0.928
‡7 cycles of TMZ 9 (8) 22.53 (21.47–23.58) 9 (6) 41.38 (10.91–71.84)
Residual tumora
6 cycles of TMZ 16 (15) 12.30 (7.28–17.31) 0.461 16 (16) 21.31 (15.34–27.29) 0.597
‡7 cycles of TMZ 22 (21) 14.56 (11.85–17.27) 22 (20) 21.80 (13.48–30.13)
Residual tumora,b
6 cycles of TMZ 7 (6) 13.44 (6.71–20.17) 0.956 7 (7) 16.20 (14.26–18.13) 0.904
‡7 cycles of TMZ 12 (12) 13.41 (11.24–15.58) 12 (12) 21.80 (6.44–37.16)
Abbreviations: CI5 confidence interval;MGMT5 O6-methylguanine DNA methyltransferase; OS5 overall survival; PFS5 progression-free survival; TMZ5
temozolomide.
a After 6 cycles of maintenance TMZ chemotherapy.
bOnly patients available for central radiology review.
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cycles of maintenance TMZ, but not, sex, KPS, or
extended TMZ treatment, were identified as signifi-
cant risk factors for survival (table 3).
Multivariate analysis was performed to address
whether extended TMZ treatment might be an inde-
pendent factor associated with survival when adjusted
Figure 1 Association of TMZ exposure with outcome
Progression-free survival (left) and overall survival (right) in patients with newly diagnosed glioblastoma by number of temo-
zolomide (TMZ) maintenance cycles: 6 cycles (group A, red curve) vs $7 cycles (group B, blue curve). (A) All patients, (B)
patients stratified by O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status, and (C and D)
patients stratified by absence vs presence of residual tumor after 6 cycles of maintenance TMZ. (C) All patients with
information on residual tumor; (D) only patients available for central radiology review.
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for known prognostic factors in glioblastoma (age,
extent of resection, KPS, MGMT promoter methyla-
tion status, IDH mutation status, and residual tumor
burden after 6 cycles of maintenance TMZ). Multi-
variate analysis revealed methylated MGMT pro-
moter status (HR 5 0.3, 95% CI 0.2–0.6), mutant
IDH status (HR 5 0.2, 95% CI 0.1–0.6), and resid-
ual tumor burden after 6 cycles of TMZ (HR 5 2.6,
95% CI 1.3–5.4) to be strongly associated with PFS,
but not older age (HR 5 0.9, 95% CI 0.5–1.9),
reduced extent of resection at first surgery (HR 5
0.8, 95% CI 0.4–1.6), reduced KPS (HR 5 1.2,
95% CI 0.6–2.2), or extended TMZ treatment beyond
6 cycles (HR 5 0.8, 95% CI 0.4–1.6) (table 4). In
addition, multivariate analysis demonstrated reduced
KPS (HR 5 2.6, 95% CI 1.3–5.0), methylated
MGMT promoter status (HR 5 0.5, 95% CI 0.3–
0.9), mutant IDH status (HR 5 0.1, 95% CI 0.0–
0.5), and residual tumor burden (HR 5 3.0, 95% CI
1.5–6.3) to be strongly associated with OS, but not
older age (HR5 1.2, 95%CI 0.6–2.5), reduced extent
of resection (HR5 0.9, 95% CI 0.4–1.8), or extended
TMZ treatment beyond 6 cycles (HR 5 1.6, 95% CI
0.8–3.3) (table 4).
DISCUSSION The current standard of care of TMZ/
RT/ TMZ with up to 6 cycles of TMZ mainte-
nance defined in 20053 was based on a phase II study
Table 3 Univariate analysis with regard to tumor progression or death
No.
PFS OS
HR (95% CI) p Value HR (95% CI) p Value
Age, y
£65 120 1 1
>65 22 1.40 (0.88–2.23) 0.158 1.89 (1.17–3.04) 0.009
Sex
Male 84 1 1
Female 58 0.84 (0.59–1.20) 0.347 0.97 (0.66–1.41) 0.874
Extent of resection
Gross total 71 1 1
Incomplete 45 1.03 (0.70–1.52) 0.888 1.01 (0.66–1.55) 0.955
Biopsy 15 2.34 (1.27–4.30) 0.006 3.42 (1.84–6.34) ,0.001
KPS, %
90–100 61 1 1
£80 55 1.28 (0.87–1.88) 0.207 1.45 (0.96–2.19) 0.082
MGMT promoter methylation status
Unmethylated 55 1 1
Methylated 77 0.46 (0.32–0.67) ,0.001 0.57 (0.39–0.84) 0.004
IDH1/2 status
Wild-type 111 1 1
Mutant 17 0.38 (0.21–0.70) 0.002 0.19 (0.08–0.46) ,0.001
Residual tumora
No 49 1 1
Yes 38 2.54 (1.60–4.04) ,0.001 3.67 (2.22–6.07) ,0.001
Residual tumora,b
No 17 1 1
Yes 19 2.15 (1.05–4.39) 0.036 4.29 (1.88–9.80) 0.001
TMZ treatment
6 cycles 81 1 1
‡7 cycles 61 0.68 (0.48–0.98) 0.036 0.74 (0.51–1.09) 0.127
Abbreviations: CI 5 confidence interval; HR 5 hazard ratio; IDH 5 isocitrate dehydrogenase; KPS 5 Karnofsky performance score; MGMT 5 O6-methyl-
guanine DNA methyltransferase; OS 5 overall survival; PFS 5 progression-free survival; TMZ 5 temozolomide.
a After 6 cycles of maintenance TMZ.
bOnly patients available for central radiology review.
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that defined the 6 cycles somewhat arbitrarily.26
Accordingly, numerous efforts of improving outcome
by intensifying adjuvant TMZ have been undertaken,
using dose intensification in the first 6 months, pro-
longation of TMZ maintenance, or both,12,27,28 all
without convincing results to suggest superiority
compared with the standard of 6 cycles at 5 of 28
days. Yet, prolonging TMZ maintenance beyond 6 to
12 months or even more has become a common prac-
tice, notably in the United States.
Here, we used the GGN cohort to identify 142
patients who completed 6 maintenance TMZ cycles
(TMZ/RT/ TMZ) without progression and then
either were followed up by observation (group A) or
continued TMZ maintenance (group B). Patient
characteristics in both groups were similar (table 1),
but 10 of 17 patients with IDH-mutant tumors be-
longed to group B, and 6 of these 10 patients were
long-term survivors (OS . 48 months). Prolonged
maintenance TMZ treatment results in better PFS
but not OS (figure 1A), whereas survival did not
differ between groups A and B analyzed in the group
of patients with a methylated MGMT promoter (fig-
ure 1B). In patients with an unmethylated MGMT
promoter methylation status, extended TMZ treat-
ment was associated with increased PFS (figure 1B),
but there were more IDH-mutant patients (n5 5) in
this subgroup than in the subgroup of unmethylated
patients who received only 6 cycles of TMZ (n 5 0)
(data not shown). This is different from the prelim-
inary analysis reported by Blumenthal et al.,13 who
found TMZ beyond 6 cycles to be linked to improved
PFS in patients with MGMT promoter–methylated
tumors.
Induction of chemoresistance by continued expo-
sure to TMZ itself may limit a potential benefit from
extending maintenance TMZ treatment. There
might be a link of a hypermutated phenotype of glio-
blastoma at the time of recurrence related to TMZ
pre-exposure.29 This hypermutated phenotype in-
volves mutations in mismatch repair pathway genes,
which are a pathway of acquired resistance to TMZ
in vitro and in vivo.30,31 Moreover, a hypermutated
phenotype of gliomas may result in progression to
Table 4 Multivariate analysis, mutually adjusted for all factors examined in this table, with regard to tumor progression or death
No.
PFS OS
HR (95% CI) p Value HR (95% CI) p Value
Age, y
£65 51 1 1
>65 12 0.92 (0.45–1.89) 0.820 1.18 (0.56–2.45) 0.671
Extent of resection
Gross total 36 1 1
Incomplete/biopsy 27 0.81 (0.41–1.60) 0.536 0.85 (0.41–1.75) 0.656
KPS, %
90–100 36 1 1
£80 27 1.18 (0.63–2.20) 0.615 2.59 (1.33–5.04) 0.005
MGMT promoter methylation status
Unmethylated 25 1 1
Methylated 38 0.34 (0.19–0.61) ,0.001 0.47 (0.25–0.91) 0.025
IDH1/2 status
Wild-type 53 1 1
Mutant 10 0.20 (0.07–0.56) 0.002 0.11 (0.03–0.52) 0.005
Residual tumora
No 40 1 1
Yes 23 2.60 (1.25–5.44) 0.011 3.04 (1.46–6.29) 0.003
TMZ treatment
6 cycles 31 1 1
‡7 cycles 32 0.82 (0.41–1.62) 0.559 1.58 (0.76–3.26) 0.218
Abbreviations: CI 5 confidence interval; HR 5 hazard ratio; IDH 5 isocitrate dehydrogenase; KPS 5 Karnofsky performance score; MGMT 5 O6-methyl-
guanine DNA methyltransferase; OS 5 overall survival; PFS 5 progression-free survival; TMZ 5 temozolomide.
a After 6 cycles of maintenance TMZ (all patients).
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a more malignant tumor phenotype at the time of
recurrence.32
In Germany and other European countries,
extended TMZ maintenance is probably most often
considered for patients with residual tumor after 6
cycles of TMZ maintenance. This was reflected by
the higher number of such patients in group B
(35.6% vs 52.4%, p 5 0.114) (table 1). However,
in these patients, no differences in PFS or OS were
observed (table 2 and figure 1, C and D). Multivariate
analysis confirmed KPS at the time of diagnosis,
MGMT promoter methylation status, IDH mutation
status, and residual tumor burden after 6 cycles of
TMZ to be associated with survival (table 4), but
not age or extent of resection, both associated with
survival in the univariate analysis (table 3).
Limitations of this study include its uncontrolled
nature, retrospective analysis albeit of prospectively
assembled data, and small sample size at least for sub-
groups. There may have been bias toward prolonging
treatment in symptomatic patients thought to be at
risk of early progression or in patients in whom there
was uncertainty as to whether there was progression
or not. However, we conclude that any potential ben-
eficial effect of prolonging maintenance TMZ would
be so small that the patient numbers required to dem-
onstrate this superiority in a randomized fashion
would be excessive.
This study indicates that in this patient cohort of
the GGN, neither PFS nor OS of patients with newly
diagnosed glioblastoma was superior when patients
received .6 cycles of maintenance TMZ. These data
may not support the practice of extending mainte-
nance TMZ chemotherapy, regardless of MGMT
promoter methylation status or residual tumor after
6 cycles.
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